3. Describe the study in your own words.
a. Why was the study done? What was the purpose of the study?
i. The purpose of this study was to examine relationship between sleep-related problems (SRPs) and anxiety disorders among children and adolescents. Previous research indicates a significant association between SRPs and anxiety disorders. However, there is limited research investigating SRPs in children and adolescents and their possible effect on functioning during the day. Therefore, this study attempts to address these discrepancies by means of an introductory inspection of various kinds of SRPs amid an abundant sample of children and adolescents with anxiety disorders. Specifically, it investigated the incidence of eight particular SRPs (insomnia, reluctance/refusal to sleep alone, reluctance/refusal to sleep away from home, nightmares, overtired without good reason, sleep less than most kids, sleeps more than most kids, and talks/walks in sleep) in the context of gender, age, and type of anxiety (generalized anxiety disorder [GAD], separation anxiety disorder [SAD], and social anxiety [SAD]), as derived from both clinician and parent evaluation. Additionally, the relationships between daytime functioning impairment (inside and outside the home), anxiety severity, and SRPs were investigated. Lastly, the effect of the pharmaceutical fluvoxamine (FLV), a selective serotonin reuptake inhibitor (SSRI), on the treatment of anxiety disorders in youth was investigated.
b. Who were the participants? Why did they select this group of children/adolescents?
i. The participants of this study included a total of 128 children and adolescents between the ages of 6 to 17. Each of these children fulfilled the Diagnostic and Statistical Manual of Mental Disorders (DSM IV-TR) criteria for one or more of the following anxiety disorders: GAD, SAD, and/or SOC. The diagnoses were determined by an interview of the parent and child with a clinician using the Schedule for Affective Disorders and Schizophrenia for School-Aged Children (K-SADS-PL). The youths were enlisted from five locations classified as Research Units in Pediatric Psychopharmacology (RUPP): New York University, New York State Psychiatric Institute/Columbia University, Duke University, Johns Hopkins School of Medicine, and University of California, Los Angeles. All youths were signed up for a double blind, placebo-controlled clinical trial of FLV for children and adolescents with anxiety disorders.
ii. There were seven specifications that eliminated some children and adolescents from participating in this study. The exclusion criteria involved were: (1) the present use of any illegal or authorized psychiatric medications, (2) prior medical care with SSRIs, (3) present diagnosis of any of the following: conduct disorder, panic disorder, post-traumatic stress disorder, obsessive compulsive disorder, major depressive disorder, or Tourette’s syndrome, (4) diagnosis of...